Key Takeaways
- Steady quarter, AI pivot formalized: Constant-currency revenue grew +1.2% QoQ while the company launched "AI First, Agile Always," an 11-program structural shift that management says will lift growth above its 10% baseline.
- GBS and AI services surged nearly 50% QoQ as customers moved from pilots to production, and 32 GenAI/Agentic AI use cases are now scaling.
- Margins inched up despite headwinds: EBITDA margin reached 20.4%, within the guided band, helped by forex and GBS profitability, even after a INR22.3 crores wage-code charge.
- Vertical mix is shifting: Healthcare and BFSI led growth; Edtech, Hi-tech and Retail declined on customer-specific completions and sector stress, though management sees stabilization ahead.
- What to watch next quarter: Whether the Q4 guidance uplift materializes, the pace of Edtech and Hi-tech stabilization, and any concrete AI First revenue numbers.
The AI First Pivot
- Structural shift, not a tagline: The 11th strategic transformation, "AI First, Agile Always," is backed by 11 strategic programs and led personally by Ashok Soota. It reframes how the company builds, delivers and scales value, with AI embedded from the start rather than bolted on.
- AI Services Delivery Platform has already moved a healthcare solution from pilot to production and is now being scaled across industries to reduce customers' own time to market.
- 32 GenAI and Agentic AI use cases have progressed beyond prototype, with several in production. New areas include Agentic AI for tech-debt remediation in enterprise applications and SaaS, now in discussion with a few customers.
- Team build-out: Plan to grow the AI/GenAI team to 1,000 by end of FY'27 while maintaining financial discipline.
- Engagement models are diversifying: Subscription or license revenue for platforms with embedded agentic AI (Arttha, Insurance in a Box); packaging the AI Delivery Platform into repeatable solutions; fixed-price projects where outcomes are clear; and outcome-based models being ideated with customers.
- Platforms carry higher gross margins: Insurance in a Box, University in a Box and multi-omics platforms are subscription/SaaS offerings at much higher gross margins than traditional services.
- India AI Summit catalyst: One leading state government has written expressing interest in an MoU for a long-term AI relationship, with a meeting planned at the summit.
Soota: "I want to assert that this development is an opportunity and not a threat for Happiest Minds, and we believe also for other IT services companies and in many ways, this reinforces the strategic choices we have been making."
Demand Environment & Pipeline
- Conversations are becoming more decisive: Enterprises are moving beyond experimentation to embedding AI into core workflows. Demand is selective but increasingly intentional, focused on workflow automation via GenAI and Agentic AI, AI-led productivity, and core-platform modernization.
- Pipeline jumped materially during the quarter, providing greater visibility for upcoming quarters.
- GenAI deals are now part of budgeted roadmaps: Customers are defining 1-to-3-year roadmaps with GenAI initiatives baked into overall budget definitions, a shift from ad-hoc experimentation.
- Deal tenure is lengthening, not shortening: Contrary to the idea of shorter AI deals, management is seeing 3-4 year engagements of higher value, such as platform support and QA testing centers of excellence, versus the historical 1-year visibility from external engineering team work.
- Productivity pass-through is not shrinking revenue: Customers are proactively asking management to drive adoption of productivity tools. Additional features and tech debt fill the capacity freed up, so throughput rises without ramp-downs. A few CTOs met in Q3 were categorical that management should not worry about revenue loss from productivity.
- Tech debt and modernization are seeing renewed customer interest as enterprises address issues long postponed, with AI at the core of repeatable solutions being built.
Segment & Vertical Performance
| Vertical | Trend | Commentary |
|---|---|---|
| BFSI | ▲ Led growth | Expecting Q4 uptick in Arttha license revenues and additional requirements from new-year planning. |
| Healthcare | ▲ Strong | Healthy growth for three quarters across geos; a health-tech company moved from discovery to GenAI buildout; a large pharma customer that ramped down in Q2 ramped up again; a medical-supplies marketplace started new initiatives. |
| Industrial | ▲ Modest uptick | Showed improvement during the quarter. |
| Edtech | ▼ Declined | Heavy exposure to higher ed, especially US universities under severe pressure; now the third-largest vertical after being the largest. Risks have mostly played out; FY'27 should see stabilization and reversal via new institution-focused AI solutions. |
| Hi-tech | ▼ Declined | A startup customer completed product development and ramped down; an Airport Authority of India support contract ended. Revenues expected to stabilize and grow in coming quarters; one large deal in advanced stage may contribute in Q4 or Q1. |
| Retail | ▼ Declined | Drop of $500,000 QoQ driven by an extra billing cycle in Q2 normalizing, a small furlough, and a completed automation project at a beverage manufacturer. Follow-up work starts Q4; pipeline is encouraging. |
- GBS turned profitable this quarter, reflecting improved execution discipline. A recently closed deal with an agentic AI platform startup carries significant upside, and the healthy pipeline with hi-tech and health-tech companies supports momentum into FY'27.
- PDES remains the largest business, anchored around product engineering and platform modernization with AI embedded. IMSS benefits from AI-enabled infrastructure management and cloud optimization via ELLIPSE and SecAiGenie platforms.
Financials & Margins
- Revenue: Q3 revenue grew 2.4% QoQ and 10.7% YoY in rupees; constant-currency growth of 1.2% sequentially and 7.1% YoY. Nine-month dollar growth stood at 10.2%, keeping to the double-digit commitment.
- EBITDA margin improved to 20.4% from 20.2% in Q2, within the guided 20-22% range. Operating margin improved 40 bps to 17.4%. Drivers: favorable forex and improved GBS profitability, partially offset by fewer working days and a INR6.2 crores forex loss.
- One-time wage-code charge of INR22.3 crores was absorbed in the quarter.
- Utilization hit 82%, the highest in recent times, reflecting better deployment, execution discipline and scaling of AI-led engagements.
- DSO rose to 92 days from 87; management is focused on collections and billing discipline to bring it back to 85 days, with January showing stabilization.
- Gross margin has been marching up for the last two quarters. Investments in the Generative AI business unit, NN sales and vertical capabilities are expected to begin paying off and contributing to margins in FY'27.
- Debt is almost entirely working-capital debt funded through preferential-rate bank borrowings at 4.6-4.7%, supported by export-oriented industry status. The current ratio is healthy.
People & Operations
- Headcount ended the quarter at 6,548. Attrition on a trailing 12-month basis stood at 17.4%, largely stable.
- Productivity tools are being evangelized proactively by management, with customers returning additional features and tech debt that the same team can absorb, so throughput increases without headcount reduction.
Happiest Health & Stake-Sale Questions
- Stake-sale rumor: Asked directly whether he was exploring a stake sale, Ashok Soota deflected, stating he is completely focused on the AI program with 11 strategic programs and "there is no change." The question was not directly answered.
- Happiest Health IPO: Soota said the IPO "could be easily 6 years away" and "at least 6 years from now," effectively ruling out any near-term timeline. Clinic expansion is underway: 6 clinics currently, targeting 26 within 12 months.
Soota: "Now we have launched a major program which I am leading here along with Joseph and the whole team is here to work with this. That change in itself has 11 strategic programs. Make no mistake, I am here to completely see it through, and there is no change."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 10%-plus constant-currency growth reaffirmed | 4-year horizon |
| EBITDA margin | Maintain 20-22% range | Current financial year |
| AI/GenAI team size | Grow to 1,000 | By end of FY'27 |
| Guidance uplift | "Significant increase" over the 10% growth commitment, with specific numbers | At Q4 results announcement |
| DSO | Bring back to 85 days | No date; January showed stabilization |
| Edtech vertical | Stabilization and reversal of downward trend | FY'27 |
| Hi-tech vertical | Stabilization and growth; one large deal in advanced stage may contribute | Q4 or Q1 FY'27 |
| Retail vertical | Uptick in revenues as follow-up work begins | Q4 |
| Investment returns | GenAI BU, NN sales and vertical capability investments to pay off and contribute to margins | FY'27 |
| Happiest Health clinics | Expand from 6 to 26 clinics | Within 12 months |
Soota: "So do look out for our announcements at the end of Q4. And I think you will see a new trajectory from the company going ahead."
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue (USD) | $65.7 million, +1.2% QoQ and +7.1% YoY in constant currency |
| Revenue (INR) | ₹588 crores, +2.4% QoQ and +10.7% YoY |
| Total income | ₹604 crores, +1.4% QoQ and +8.9% YoY |
| EBITDA | ₹123 crores, margin 20.4% vs 20.2% in Q2 |
| Operating margin | 17.4%, up 40 bps sequentially from 17% |
| Profit before tax | ₹54.2 crores |
| Profit after tax | ₹40.3 crores |
| Adjusted PAT margin | 11.6%, up from 11% in Q2 |
| One-time wage code charge | ₹22.3 crores, impacted PAT |
| Forex loss | ₹6.2 crores |
| 9-month revenue (USD) | $195.2 million, +10.2% YoY |
| 9-month revenue (INR) | ₹1,711 crores, +12.8% YoY |
| 9-month EBITDA margin | 20.6% |
| 9-month adjusted PAT | ₹208 crores, vs ₹195 crores in prior year |
| GBS and AI services revenue growth | ~50% QoQ |
| IP-led sales | 10.4% of revenue |
| Utilization | 82%, highest in recent times, up from 80% |
| Attrition (trailing 12-month) | 17.4%, largely stable |
| Headcount | 6,548 employees |
| DSO | 92 days, up from 87 in Q2; target to bring back to 85 days |
| ROCE | 22% |
| ROE | 12% |
| Liquidity | ₹1,520 crores |
| GenAI and Agentic AI use cases | 32 moved from prototype, several scaling into production |
| New logos (H1 FY26) | 13, highest ever |
| AI/GenAI team target | 1,000 Happiest Minds by end of FY27 |
| Full-year revenue growth guidance | 10% plus in constant currency |
| EBITDA margin guided range | 20% to 22% |